Brookline analyst Kumaraguru Raja initiated coverage of Unicycive Therapeutics with a Buy rating and $8 price target. Unicycive is developing Oxylanthanum Carbonate for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis and UNI-494 for treatment of acute kidney injury, or AKI, notes the analyst, who values shares based on the valuation of the commercial potential of OLC in hyperphosphatemia and UNI-494 in prevention of delayed graft function, or DGF, in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics files to sell 50M shares of common stock for holders
- Unicycive Therapeutics joins Russell Microcap Index
- Unicycive Therapeutics Joins Russell Microcap® Index
- Unicycive Therapeutics Reports Clinical Trial Breakthrough
- Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial